Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 43.52% is 242% above its 5-year average of -30.60%, near the high end of its 5-year range (-76.26%–43.52%).
251.03% above its 12-month average of -28.82%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 4.61%.
RETURN ON ASSETS (ROA)
43.52%
RETURN ON ASSETS (ROA) AVG TTM
-28.82%
RETURN ON ASSETS (ROA) AVG 3Y
-20.19%
RETURN ON ASSETS (ROA) AVG 5Y
-30.60%
RETURN ON ASSETS (ROA) AVG 10Y
-61.44%
RETURN ON ASSETS (ROA) AVG 15Y
-82.07%
RETURN ON ASSETS (ROA) AVG 20Y
-64.17%
CURRENT VS TTM AVG
+251.03%
CURRENT VS 3Y AVG
+315.55%
CURRENT VS 5Y AVG
+242.23%
CURRENT VS 10Y AVG
+170.83%
CURRENT VS 15Y AVG
+153.03%
CURRENT VS 20Y AVG
+167.82%
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+234.88%
vs the sector median at left
Omeros Corporation
Market Cap
$1.34B
Return on Assets (ROA)
43.52%
TTM Avg
-28.82%
3Y Avg
-20.19%
5Y Avg
-30.60%
Market Cap
$1.33B
Return on Assets (ROA)
-32.81%
TTM Avg
-32.81%
3Y Avg
-32.81%
5Y Avg
-32.81%
Market Cap
$1.37B
Return on Assets (ROA)
-89.60%
TTM Avg
418.97%
3Y Avg
177.41%
5Y Avg
100.38%
Market Cap
$1.31B
Return on Assets (ROA)
-68.96%
TTM Avg
-38.41%
3Y Avg
-33.02%
5Y Avg
-35.57%
Market Cap
$1.39B
Return on Assets (ROA)
3.12%
TTM Avg
3.19%
3Y Avg
2.54%
5Y Avg
2.30%
Market Cap
$1.40B
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Return on Assets (ROA)
-21.52%
TTM Avg
-21.52%
3Y Avg
-21.52%
5Y Avg
-21.52%
Market Cap
$1.40B
Return on Assets (ROA)
-31.81%
TTM Avg
-43.72%
3Y Avg
-70.87%
5Y Avg
-63.61%
Market Cap
$1.42B
Return on Assets (ROA)
61.75%
TTM Avg
-16.82%
3Y Avg
-22.73%
5Y Avg
-17.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Omeros Corporation (OMER) | $1.34B | 43.52% | -28.82% | -20.19% | -30.60% |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.33B | -32.81% | -32.81% | -32.81% | -32.81% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -89.60% | 418.97% | 177.41% | 100.38% |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | -68.96% | -38.41% | -33.02% | -35.57% |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 3.12% | 3.19% | 2.54% | 2.30% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | -21.52% | -21.52% | -21.52% | -21.52% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | -31.81% | -43.72% | -70.87% | -63.61% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 61.75% | -16.82% | -22.73% | -17.45% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | -46.39% | -37.70% | -40.46% | -33.71% |
ROA
43.5%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -1.03% |
| 2024-12-31 | -56.60% |
| 2023-12-31 | -31.15% |
| 2022-12-31 | 8.02% |
| 2021-12-31 | -26.57% |
| 2020-12-31 | -76.26% |
| 2019-12-31 | -61.68% |
| 2018-12-31 | -132.13% |
| 2017-12-31 | -45.97% |
| 2016-12-31 | -99.21% |
| 2015-12-31 | -153.27% |
| 2014-12-31 | -664.32% |
| 2013-12-31 | -240.68% |
| 2012-12-31 | -144.66% |
| 2011-12-31 | -105.80% |
| 2010-12-31 | -64.00% |
| 2009-12-31 | -33.98% |
| 2008-12-31 | -109.90% |
| 2007-12-31 | -85.01% |
| 2006-12-31 | 0.00% |
| 2005-12-31 | 0.00% |
